How does peripheral nerve decompression surgery, such as common peroneal nerve release, help patients with refractory restless‑legs syndrome?

Peripheral Nerve Decompression Surgery for Restless Legs Syndrome

Current Guideline Position

Peripheral nerve decompression surgery (such as common peroneal nerve release) is not recommended in current evidence-based guidelines for restless legs syndrome. The 2025 American Academy of Sleep Medicine clinical practice guideline—the highest-quality, most recent evidence—does not include surgical nerve decompression among recommended treatments for RLS 1, 2, 3.

Why the Claim Exists: Theoretical Rationale

The hypothesis behind nerve decompression surgery stems from observations that:

• Secondary RLS is often associated with peripheral neuropathy, and some patients report overlapping symptoms of nerve compression and RLS 4.
• Anatomic variants at the fibular head (fibrous bands on the peroneus longus muscle in 30–78% of cases) can compress the common peroneal nerve 5.
• A 2017 retrospective case series of 42 patients who underwent common and superficial fibular nerve decompression for peripheral neuropathy reported significant improvement in symptoms commonly associated with RLS—including "twitchy/jumpy," "uneasy," "creepy/crawly," and "throbbing" sensations—at 15 weeks post-surgery 4.

However, this study had critical limitations: it was uncontrolled, retrospective, used non-validated visual analog scales rather than RLS-specific diagnostic criteria or severity measures, and did not confirm that patients met all four essential diagnostic criteria for RLS (urge to move with uncomfortable sensations, worsening at rest, relief with movement, circadian worsening) 2, 4.

Evidence-Based Treatment Algorithm for RLS

The 2025 AASM guideline establishes a clear hierarchy 1, 2, 3:

Step 1: Iron Assessment and Repletion

• Check morning fasting serum ferritin and transferrin saturation after withholding iron supplements ≥24 hours 2, 3.
• Supplement if ferritin ≤75 ng/mL or transferrin saturation <20% (adults) or ferritin <50 ng/mL (children) 2, 3.
• Oral ferrous sulfate 325 mg daily (conditional recommendation, moderate certainty) or IV ferric carboxymaltose 750–1000 mg (strong recommendation, moderate certainty) 2, 3.

Step 2: First-Line Pharmacologic Therapy

• Alpha-2-delta ligands (gabapentin, gabapentin enacarbil, or pregabalin) are strongly recommended as first-line treatment (strong recommendation, moderate certainty of evidence) 1, 2, 3.
• Gabapentin dosing: start 300 mg TID, titrate by 300 mg/day every 3–7 days to maintenance 1800–2400 mg/day divided TID, maximum 3600 mg/day 2, 3.
• Pregabalin offers twice-daily dosing with superior bioavailability 2, 3.

Step 3: Avoid Dopamine Agonists

• The AASM suggests against routine use of pramipexole, ropinirole, and rotigotine due to 7–10% annual augmentation risk (conditional recommendation, moderate certainty) 1, 2, 3.

Step 4: Refractory Cases

• Extended-release oxycodone and other low-dose opioids (methadone 5–10 mg daily, buprenorphine) are conditionally recommended for moderate-to-severe refractory RLS after optimizing iron and trialing alpha-2-delta ligands 1, 2, 3.
• Bilateral high-frequency peroneal nerve stimulation (a non-invasive wearable device placed below the knees) receives a conditional recommendation based on short-term sham-controlled studies 1, 2, 3.

Why Nerve Decompression Surgery Is Not Guideline-Recommended

• No randomized controlled trials have compared nerve decompression surgery to sham surgery or medical therapy using validated RLS diagnostic criteria and severity scales 4.
• The single retrospective case series 4 cannot distinguish true RLS from peripheral neuropathy mimics (which present with constant symptoms not relieved by movement and no circadian pattern) 2.
• Bilateral high-frequency peroneal nerve stimulation—a non-invasive, reversible intervention targeting the same anatomic region—has higher-quality evidence (sham-controlled trials) and is conditionally recommended 1, 2.
• Surgical decompression carries irreversible risks (nerve injury, infection, scarring) without proven benefit for true RLS 5.

Critical Diagnostic Pitfall

Do not diagnose RLS without all four essential criteria being present 2:

1. Urge to move the legs accompanied by uncomfortable sensations.
2. Symptoms begin or worsen during rest or inactivity.
3. Partial or total relief with movement.
4. Worsening in the evening or night.

Peripheral neuropathy mimics RLS but has constant symptoms, no relief with movement, and no circadian pattern 2. Patients with true peripheral neuropathy may benefit from nerve decompression, but this does not validate surgery for idiopathic RLS 4.

Non-Pharmacologic Alternatives with Evidence

A 2019 systematic review identified non-surgical interventions with some evidence for RLS 6:

• Repetitive transcranial magnetic stimulation, exercise, compression devices (pneumatic sequential compression worn for 1 hour before symptom onset improved RLS severity and quality of life in a small pilot study 7), counterstrain manipulation, infrared therapy, and standard acupuncture significantly reduced RLS severity compared to controls 6.
• However, the quality of evidence was not high, and these interventions are not included in the 2025 AASM guideline as standard recommendations 1, 6.

Bottom Line

Peripheral nerve decompression surgery for RLS lacks the evidence base required for guideline inclusion and should not be offered outside of research protocols. The 2025 AASM guideline provides a robust, evidence-based treatment algorithm prioritizing iron repletion, alpha-2-delta ligands, and—for refractory cases—low-dose opioids or non-invasive peroneal nerve stimulation 1, 2, 3. Patients considering surgery should first undergo rigorous diagnostic confirmation that they meet all four RLS criteria (not neuropathy mimics), optimize iron status, and trial guideline-recommended therapies 2, 3.